Current perspectives in muscle invasive bladder cancer

European Journal of Cancer

Volumn 38, Issue 4, 2002, Pages 460-467

  Sternberg, C N ^a  

^a Vincenzo Pansadoro Foundation   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; BLADDER CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER SURVIVAL; CYSTECTOMY; DRUG EFFECT; HUMAN; MEDICAL SPECIALIST; MULTIMODALITY CANCER THERAPY; ORGAN PRESERVATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 0036188917     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00393-8     Document Type: Article

References (52)

1. Chemotherapy and management of bladder tumors
2. Prognostic factors of outcome after radical cystectomy for bladder cancer: A retrospective study of a homogeneous patient cohort
3. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1.054 patients
4. Cystectomy for bladder cancer: A contemporary series
5. Neo-adjuvant and adjuvant chemotherapy in locally advanced disease: What are the effects on survival and prognosis?
6. Neo-adjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: A randomised controlled trial
7. SWOG 8710 (INT-0080): Randomized phase III trial of neo-adjuvant M-VAC and cystectomy versus cystectomy alone in patients with locally advanced bladder cancer
8. Neo-adjuvant chemotherapy is not (yet) standard treatment for muscle invasive bladder cancer
9. Neo-adjuvant chemotherapy in invasive bladder cancer. Trial design
10. Feasibility of transurethral resection for muscle infiltrating carcinoma of the bladder: Long-term followup of a prospective study
11. Transurethral resection of muscle-invasive bladder cancer: 10-Year outcome
12. Neo-adjuvant M-VAC of invasive bladder cancer: The G.U.O.N.E. multicenter phase III trial
13. Neo-adjuvant treatment for locally advanced bladder cancer: A randomized prospective clinical trial
14. Five year follow-up of a prospective trial of radical cystectomy and neo-adjuvant chemotherapy
15. Neo-adjuvant cisplatin-methotrexate chemotherapy of invasive bladder cancer. Nordic cystectomy trial 2
16. Transitional cell carcinoma of the urinary tract: Bladder preserving treatments: Chemotherapy and conservative surgery
17. Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder
18. Radical TUR and chemotherapy aiming at bladder preservation
19. European organization for research and treatment of cancer genitourinary group phase 2 study of chemotherapy in stage T3-4N0-xM0 transitional cell cancer of the bladder: Evaluation of clinical response
20. Can we select patients for bladder preservation based upon response to chemotherapy?
21. Combined modality program with possible organ preservation for invasive bladder carcinoma: Results of RTOG protocol 85-12
22. Bladder preservation by combined modality therapy for invasive bladder cancer
23. Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: A Southwest Oncology Group study
24. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: A prospective comparative trial
25. Advanced bladder cancer (stages pT3b, pT4a, pN1 nad pN2): Improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy results of a controlled prospective study
26. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: Long term results of a controlled prospective study and further clinical experience
27. Adjuvant chemotherapy in locally advanced bladder cancer (PT3/PN1-2,M0) - A phase III study
28. The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: What we do not know and why
29. M-VAC for advanced transitional cell carcinoma of the urothelium: Efficacy, and patterns of response and relapse
30. Randomized phase III trial of high dose intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European organization for research and treatment of cancer
31. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study
32. p53 and treatment of bladder cancer
33. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53
34. Differences in gene expression in muscle-invasive bladder cancer: A comparison of Italian and American patients
35. Reproducibility of p53 immunohistochemistry in bladder tumors
36. Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder
37. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation
38. Neo-adjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: Prospective randomized phase III study
39. Alternating chemo-radiotherapy in bladder cancer: A conservative approach
40. Neo-adjuvant chemotherapy in treatment of invasive transitional bladder cancer: A controlled, prospective randomised study
41. Neo-adjuvant combined modality program with selective organ preservation for invasive bladder cancer: Results of Radiation Therapy Oncology Group phase II trial 8802
42. Phase III trial of neo-adjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: Initial results of Radiation Therapy Oncology Group 89-03
43. Muscle-invasive bladder cancer: Transurethral resection and radiochemotherapy as an organ-sparing treatment option
44. Biological selection for organ conservation
45. Concomitant fluorouracil (5-FU)-cisplatin (CDDP) and bifractionated split course radiation therapy (BSCRT) for invasive bladder cancer
46. Altered fractionation in chemo-radiation for bladder cancer
47. Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: An update
48. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: Results of a prospective randomized trial
49. Adjuvant chemotherapy in advanced bladder cancer
50. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer